Evidence map›Paper›PMID 39516395›Full record

ArticleJournal of cancer research and clinical oncology2024

Five-year overall survival of early- and late-onset colorectal cancer in Medellín, Colombia: a comparative study.

Álvaro Esteban Ruiz-Grajales, Juan Camilo Correa-Cote, Miguel Ángel Sánchez-Zapata, Manuela María Orozco-Puerta, Juan Felipe Baena-García, Esteban Castrillón-Martínez

Abstract readComparative Study
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Álvaro Esteban Ruiz-GrajalesSemillero de Investigación en Salud (SEIS), Facultad de Medicina, Universidad de Antioquia UdeA, St. 51D # 62-29, Medellín, 050010470, Colombia. aesteban.ruiz@udea.edu.co.ORCID http://orcid.org/0000-0001-6409-9204
Juan Camilo Correa-CoteClínica Medellín S.A.S, Medellín, Colombia.ORCID http://orcid.org/0000-0001-5228-4007
Miguel Ángel Sánchez-ZapataSemillero de Investigación en Salud (SEIS), Facultad de Medicina, Universidad de Antioquia UdeA, St. 51D # 62-29, Medellín, 050010470, Colombia.ORCID http://orcid.org/0009-0007-7298-2954
Manuela María Orozco-PuertaSemillero de Investigación en Salud (SEIS), Facultad de Medicina, Universidad de Antioquia UdeA, St. 51D # 62-29, Medellín, 050010470, Colombia.ORCID http://orcid.org/0009-0006-5938-7205
Juan Felipe Baena-GarcíaSemillero de Investigación en Medicina Interna (SIMI), Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, Colombia.ORCID http://orcid.org/0009-0002-0460-9107
Esteban Castrillón-MartínezSemillero de Investigación en Salud (SEIS), Facultad de Medicina, Universidad de Antioquia UdeA, St. 51D # 62-29, Medellín, 050010470, Colombia.ORCID http://orcid.org/0000-0001-6875-5918

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEarly-onset colorectal cancer (CRC) (EOCRC, < 50 years) has distinct clinicopathological features from late-onset CRC (LOCRC, ≥ 50 years). However, evidence on survival outcomes is contradictory. We aimed to analyse the differences in 5-year overall survival (OS) between EOCRC and LOCRC.

methodsA retrospective cohort study was conducted during 2018-2022. Individuals aged ≥ 18 years diagnosed with CRC at two hospitals in Medellín, Colombia were included. Clinicopathological and survival data were retrieved from the medical records and a public government database. Patients were categorized into EOCRC and LOCRC groups. Five-year OS rates were calculated using the Kaplan-Meier method and prognostic factors for OS were identified through Cox regression models.

resultsAmong 1022 patients, 52.5% were female, and 13.5% (n = 138) had EOCRC. Patients with EOCRC showed higher 5-year OS rates than LOCRC patients (54% vs. 32%). Univariable analyses indicated a 37% lower risk of death for EOCRC compared to LOCRC (HR: 0.633, 95%CI: 0.476-0.840, p = 0.002). After multivariable analyses, advanced staging and higher tumour grading were prognostic factors for worse OS (HR: 2.127, 95% CI:1.405-3.220, p = 0.0001; and HR: 12.896, 95%CI: 6.310-26.355, p = 0.000; respectively), and being in the EOCRC group remained as a prognostic factor for higher OS (HR: 0.482, 95% CI: 0.336-0.690, p = 0.000).

conclusionEOCRC is associated with significantly better 5-year OS rates and prognosis compared to LOCRC. Advanced stage and higher tumour grading are predictors of lower OS among all CRC patients. These findings highlight the importance of age-related risk stratification and personalized therapeutic approaches in CRC.

Indexed as

Age of OnsetColorectal NeoplasmsAdultAgedColombiaFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesSurvival RateAge of onsetColombiaColorectal neoplasmsEpidemiologySurvival analysis

Identifiers

PMID39516395
PMCPMC11549184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.